Skip Nav Destination
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases
Issue Archive
January 13 2011
In this Issue
Table of Contents
Inside blood
Review Article
Clinical Trials and Observations
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
Clinical Trials & Observations
Jacalyn Rosenblatt,Baldev Vasir,Lynne Uhl,Simona Blotta,Claire MacNamara,Poorvi Somaiya,Zekui Wu,Robin Joyce,James D. Levine,Dilani Dombagoda,Yan Emily Yuan,Karen Francoeur,Donna Fitzgerald,Paul Richardson,Edie Weller,Kenneth Anderson,Donald Kufe,Nikhil Munshi,David Avigan
Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma
Clinical Trials & Observations
Yingtai Chen,Tongzhang Zheng,Qing Lan,Francine Foss,Christopher Kim,Xuezhong Chen,Min Dai,Yumin Li,Theodore Holford,Brian Leaderer,Peter Boyle,Stephen J. Chanock,Nathaniel Rothman,Yawei Zhang
Hematopoiesis and Stem Cells
Enhanced c-Met activity promotes G-CSF–induced mobilization of hematopoietic progenitor cells via ROS signaling
Melania Tesio,Karin Golan,Simona Corso,Silvia Giordano,Amir Schajnovitz,Yaron Vagima,Shoham Shivtiel,Alexander Kalinkovich,Luisa Caione,Loretta Gammaitoni,Elisa Laurenti,Eike C. Buss,Elias Shezen,Tomer Itkin,Orit Kollet,Isabelle Petit,Andreas Trumpp,James Christensen,Massimo Aglietta,Wanda Piacibello,Tsvee Lapidot
Immunobiology
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3
Sofie Struyf,Laura Salogni,Marie D. Burdick,Jo Vandercappellen,Mieke Gouwy,Sam Noppen,Paul Proost,Ghislain Opdenakker,Marc Parmentier,Craig Gerard,Silvano Sozzani,Robert M. Strieter,Jo Van Damme
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
Makiko Hirai,Norimitsu Kadowaki,Toshio Kitawaki,Haruyuki Fujita,Akifumi Takaori-Kondo,Ryutaro Fukui,Kensuke Miyake,Takahiro Maeda,Shimeru Kamihira,Yoshiki Miyachi,Takashi Uchiyama
Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain
Katharina Lückerath,Vladimir Kirkin,Inga Maria Melzer,Frederic B. Thalheimer,Dagmar Siele,Wiebke Milani,Thure Adler,Antonio Aguilar-Pimentel,Marion Horsch,Geert Michel,Johannes Beckers,Dirk H. Busch,Markus Ollert,Valerie Gailus-Durner,Helmut Fuchs,Martin Hrabĕ de Angelis,Frank J. T. Staal,Krishnaraj Rajalingam,Anne-Odile Hueber,Lothar J. Strobl,Ursula Zimber-Strobl,Martin Zörnig
Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells
Yohei Iwata,Takashi Matsushita,Mayuka Horikawa,David J. DiLillo,Koichi Yanaba,Guglielmo M. Venturi,Paul M. Szabolcs,Steven H. Bernstein,Cynthia M. Magro,Armistead D. Williams,Russell P. Hall,E. William St Clair,Thomas F. Tedder
Lymphoid Neoplasia
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
Patricia Pérez-Galán,Helena Mora-Jensen,Marc A. Weniger,Arthur L. Shaffer, III,Edgar G. Rizzatti,Colby M. Chapman,Clifton C. Mo,Lawrence S. Stennett,Christoph Rader,Poching Liu,Nalini Raghavachari,Maryalice Stetler-Stevenson,Constance Yuan,Stefania Pittaluga,Irina Maric,Kieron M. Dunleavy,Wyndham H. Wilson,Louis M. Staudt,Adrian Wiestner
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu,Patricia Pérez-Galán,Delong Liu,Angélique Biancotto,Stefania Pittaluga,Berengere Vire,Federica Gibellini,Ndegwa Njuguna,Elinor Lee,Lawrence Stennett,Nalini Raghavachari,Poching Liu,J. Philip McCoy,Mark Raffeld,Maryalice Stetler-Stevenson,Constance Yuan,Richard Sherry,Diane C. Arthur,Irina Maric,Therese White,Gerald E. Marti,Peter Munson,Wyndham H. Wilson,Adrian Wiestner
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brief Report
Brian J. Lannutti,Sarah A. Meadows,Sarah E. M. Herman,Adam Kashishian,Bart Steiner,Amy J. Johnson,John C. Byrd,Jeffrey W. Tyner,Marc M. Loriaux,Mike Deininger,Brian J. Druker,Kamal D. Puri,Roger G. Ulrich,Neill A. Giese
Myeloid Neoplasia
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Clinical Trials & Observations
Raphael Itzykson,Sylvain Thépot,Bruno Quesnel,Francois Dreyfus,Odile Beyne-Rauzy,Pascal Turlure,Norbert Vey,Christian Recher,Caroline Dartigeas,Laurence Legros,Jacques Delaunay,Célia Salanoubat,Sorin Visanica,Aspasia Stamatoullas,Francoise Isnard,Anne Marfaing-Koka,Stephane de Botton,Youcef Chelghoum,Anne-Laure Taksin,Isabelle Plantier,Shanti Ame,Simone Boehrer,Claude Gardin,C. L. Beach,Lionel Adès,Pierre Fenaux,on behalf of the Groupe Francophone des Myelodysplasies (GFM)
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells
Christopher G. Kanakry,Allan D. Hess,Christopher D. Gocke,Christopher Thoburn,Ferdynand Kos,Christian Meyer,Janet Briel,Leo Luznik,B. Douglas Smith,Hyam Levitsky,Judith E. Karp
Phagocytes, Granulocytes, and Myelopoiesis
Platelets and Thrombopoiesis
Red Cells, Iron, and Erythropoiesis
Thrombosis and Hemostasis
Transfusion Medicine
Transplantation
First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases
Clinical Trials & Observations
M. Louise Markert,José G. Marques,Bénédicte Neven,Blythe H. Devlin,Elizabeth A. McCarthy,Ivan K. Chinn,Adriana S. Albuquerque,Susana L. Silva,Claudio Pignata,Geneviève de Saint Basile,Rui M. Victorino,Capucine Picard,Marianne Debre,Nizar Mahlaoui,Alain Fischer,Ana E. Sousa
Vascular Biology
-
Cover Image
Cover Image
![issue cover]()
The structure of IRS-2. The picture shows the overall 3-dimensional structure of IRS-2, which is the first example of a parasitic serpin. IRS-2 expression is up-regulated in tick salivary glands upon attachment to the vertebrate host, and the protein inhibits host platelet aggregation and acute inflammation. IRS-2 targets specifically human cathepsin G and chymase, which is a novel mechanism of action for an exogenous protein. The molecular, cellular, and structural aspects of IRS-2 interference with the host defense mechanisms, as well as its potential future pharmaceutical applications, are detailed in the article by Chmelar et al on page 736.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
